CatalYm announced the publication of preclinical data in Nature Communications.
The study reveals a central role of GDF-15 in the resistance of tumours to current immunotherapy.
These findings further highlight the therapeutic significance of CatalYm’s proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies.
This foundational research, which was performed together with founder Jörg Wischhusen and collaborators, is the first to describe a mechanistic link between tumour-produced Growth Differentiation Factor-15 (GDF-15) and the LFA-1/ICAM-1 cell adhesion axis.
The interaction between LFA-1/ICAM-1 is a critical step in the infiltration of T cells into the tumour microenvironment.
This is essential for the extravasation of T cells from the blood vessels into the surrounding tissue.
GDF-15 is primarily known for its function in foeto-maternal tolerance, an immunosuppressive mechanism that protects the foetus from the mother’s immune system.
The researchers demonstrated that GDF-15 blocks LFA-1-dependent T cell recruitment into the tumour microenvironment, a prerequisite for responses to anti-PD-1/-L1 treatment but also other immunotherapeutic strategies.
Conversely, the blockade of GDF-15 with antibodies like the anti-GDF-15 antibody visugromab improved T cell infiltration into tumours.
Combined with a PD-1 inhibitor, it increased tumour clearance and survival with a synergistic effect.
In line with these findings, serum analysis of melanoma patients showed that response to anti-PD-1 negatively correlates with GDF-15 serum levels.
Therefore, GDF-15 serum levels may be a predictive biomarker for the response to anti-PD-1 therapy and overall survival in these patients.
These findings further underscore the immunosuppressive role of GDF-15 in the tumour and contribute to the growing body of data supporting GDF-15-neutralising therapy as a promising approach for hard-to-treat tumours resistant or refractory to anti-PD-1/-L1 treatment.
"Our publication is the first to demonstrate the effect of tumour-derived GDF-15 on the LFA-1/ICAM-1 axis. As this axis orchestrates cell-cell-interactions that are essential for immune-mediated tumour control, GDF-15 likely contributes to immune escape across many different tumours and therapies,” said Prof Dr Jörg Wischhusen, Co-Founder of CatalYm and Professor at the Julius-Maximilians-University Würzburg, who is the senior author of the publication.
“Unravelling the details of the underlying biologic pathways is crucial to develop effective therapeutic approaches that can reverse tumour-mediated immunosuppression resulting in drug resistance, one of the major challenges in cancer medicine. We are committed to rapidly advancing our phase 2 evaluation of visugromab on our mission to expand the treatment horizon for current and future immunotherapies,” added Dr Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm.
The published data adds further valuable mechanistic understanding to the clinical findings from CalaYm’s GDFather (GDF-15 Antibody-mediaTed Human Effector Cell Relocation) trials with visugromab in combination with the anti-PD-1 inhibitor nivolumab in patients with advanced solid tumours.
The phase 1 (NCT04725474) study results announced in September 2022 showed an excellent safety and tolerability profile as well as significant clinical benefit in last-line tumour patients that were anti-PD-1/-L1 relapsed or refractory.
Interim data from the phase 2 (NCT04725474) trial recently presented at ASCO continue to demonstrate a very good safety and tolerability profile and promising early responses in major cancer indications, including non-small cell lung cancer (NSCLC), bladder cancer and hepatocellular carcinoma (HCC).
Mature data readouts for efficacy and safety data of the core phase 2a program as well as main biomarker-correlations are expected to become available by late 2023.
Source: Trophic Communications
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.